GenFleet Therapeutics Advances RAS-Targeted Therapy with GFH276 Trial

Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has shared an announcement.

GenFleet Therapeutics has announced the dosing of the first patient in a phase I/II trial for GFH276, a molecular glue Pan RAS (ON) inhibitor, targeting advanced solid tumors with RAS mutations. This development marks a significant step in the company’s RAS-targeted therapy pipeline, as GFH276 is among the top three clinical-stage molecules in the global Pan RAS (ON) landscape. The trial aims to assess the safety, tolerability, and preliminary efficacy of GFH276, which has shown promising pharmacokinetic properties and potential to overcome drug resistance in preclinical studies.

More about Genfleet Therapeutics (Shanghai), Inc. Class H

GenFleet Therapeutics (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer therapies. The company specializes in RAS-targeted treatments, with a pipeline that includes molecular glue inhibitors and ADCs aimed at various RAS mutations.

Average Trading Volume: 8,437,074

See more insights into 2595 stock on TipRanks’ Stock Analysis page.